HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes
Data(s) |
01/08/2014
|
---|---|
Resumo |
<p>OBJECTIVE: Low HDL cholesterol (HDL-C) and small HDL particle size may directly promote hyperglycemia. We evaluated associations of HDL-C, apolipoprotein A-I (apoA-I), and HDL-C/apoA-I with insulin secretion, insulin resistance, HbA1c, and long-term glycemic deterioration, reflected by initiation of pharmacologic glucose control.</p><p>RESEARCH DESIGN AND METHODS: The 5-year Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study followed 9,795 type 2 diabetic subjects. We calculated baseline associations of fasting HDL-C, apoA-I, and HDL-C/apoA-I with HbA1c and, in those not taking exogenous insulin (n = 8,271), with estimated β-cell function (homeostasis model assessment of β-cell function [HOMA-B]) and insulin resistance (HOMA-IR). Among the 2,608 subjects prescribed lifestyle only, Cox proportional hazards analysis evaluated associations of HDL-C, apoA-I, and HDL-C/apoA-I with subsequent initiation of oral hypoglycemic agents (OHAs) or insulin.</p><p>RESULTS: Adjusted for age and sex, baseline HDL-C, apoA-I, and HDL-C/apoA-I were inversely associated with HOMA-IR (r = -0.233, -0.134, and -0.230; all P < 0.001; n = 8,271) but not related to HbA1c (all P > 0.05; n = 9,795). ApoA-I was also inversely associated with HOMA-B (r = -0.063; P = 0.002; n = 8,271) adjusted for age, sex, and HOMA-IR. Prospectively, lower baseline HDL-C and HDL-C/apoA-I levels predicted greater uptake (per 1-SD lower: hazard ratio [HR] 1.13 [CI 1.07-1.19], P < 0.001; and HR 1.16 [CI 1.10-1.23], P < 0.001, respectively) and earlier uptake (median 12.9 and 24.0 months, respectively, for quartile 1 vs. quartile 4; both P < 0.01) of OHAs and insulin, with no difference in HbA1c thresholds for initiation (P = 0.87 and P = 0.81). Controlling for HOMA-IR and triglycerides lessened both associations, but HDL-C/apoA-I remained significant.</p><p>CONCLUSIONS: HDL-C, apoA-I, and HDL-C/apoA-I were associated with concurrent insulin resistance but not HbA1c. However, lower HDL-C and HDL-C/apoA-I predicted greater and earlier need for pharmacologic glucose control.</p> |
Identificador | |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/closedAccess |
Fonte |
Waldman , B , Jenkins , A J , Davis , T M E , Taskinen , M-R , Scott , R , O'Connell , R L , Gebski , V J , Ng , M K C , Keech , A C & FIELD Study Investigators 2014 , ' HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes ' Diabetes Care , vol 37 , no. 8 , pp. 2351-8 . DOI: 10.2337/dc13-2738 |
Palavras-Chave | #Aged #Apolipoprotein A-I #Blood Glucose #Cholesterol, HDL #Cross-Sectional Studies #Diabetes Mellitus, Type 2 #Disease Progression #Female #Fenofibrate #Follow-Up Studies #Humans #Hypoglycemic Agents #Insulin #Insulin Resistance #Insulin-Secreting Cells #Male #Middle Aged #Prognosis #Treatment Outcome |
Tipo |
article |